Castle Creek Pharmaceuticals

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Castle Creek Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials none currently recruiting 6 completed early-phase tilt upper quartile by trial count

Castle Creek Pharmaceuticals: 7 sponsored US clinical trials, none currently recruiting.

Castle Creek Pharmaceuticals sponsors 7 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Epidermolysis Bullosa (EB), with 1 trials.

Upper-quartile sponsor footprint

Castle Creek Pharmaceuticals sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

7 total, page 1 of 1

COMPLETED Phase 1

To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB)

NCT03472287
COMPLETED Phase 1

A Study of Sensitizing Potential of Diacerein 1% Ointment in Healthy Subjects

NCT03472547
COMPLETED Phase 1

A 21 Day Irritation Study in Healthy Volunteers With Diacerein 1% Ointment

NCT03472534
COMPLETED Phase 1

A 6-Week Study to Evaluate the Photoallergic Potential of Diacerein 1% Ointment in Healthy Volunteers

NCT03473197
COMPLETED Phase 1

A 4-Day Study to Evaluate the Photoxicity of Diacerein 1% Topical Ointment in Healthy Volunteers

NCT03473184
COMPLETED Phase 2

Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex

NCT03389308
TERMINATED Phase 2

Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)

NCT03154333

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 2

Therapeutic Areas

Epidermolysis Bullosa (EB) 1
Epidermolysis Bullosa Simplex 1
Junctional Epidermolysis Bullosa 1
Dystrophic Epidermolysis Bullosa 1
Healthy 1

How the Castle Creek Pharmaceuticals early-phase archive is shaped

7 indexed studies, none listed as recruiting (0% open); 6 completed (86%).

Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: Epidermolysis Bullosa (EB) (1 trial), 4 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Castle Creek Pharmaceuticals: archived-pipeline peers nationwide

Peers matched on 7 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Castle Creek Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Castle Creek Pharmaceuticals3M4Life Research89bioAbbott Diagnostics Division10xBio22nd Century Group23andMe3-C Institute for Social Development
Castle Creek Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Castle Creek Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Castle Creek Pharmaceuticals page

7 registered trials is a research-attention snapshot, not an endorsement of Castle Creek Pharmaceuticals or any single study.

  • None of Castle Creek Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Epidermolysis Bullosa (EB) is the condition Castle Creek Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Epidermolysis Bullosa (EB) trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Castle Creek Pharmaceuticals pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.